Wise, D. R., Zhang, T., Saraiya, B., Avitia, J. W., Armstrong, A. J., Gulati, S., Bupathi, M., Sokolova, A., Tutrone, R., Shpyro, S., Blokhina, O., Wang, Q., Liu, Y., Durbin, J., Zheng, P., Stein, M. N. (2026). Updated efficacy results from the phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.175